[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100609901":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":64,"collaborators":19,"id":66,"slug":19,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":19,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":19,"maxAge":19,"enrollmentInfo":73,"targetDuration":19,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"PepGen Inc","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PGN-EDODM1","EXPERIMENTAL","Participants will receive doses of PGN-EDODM1 once every 4 weeks (Q4W)",[13],"Drug: PGN-EDODM1",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Administered by intravenous (IV) infusion",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"PepGen Patient Advocacy","CONTACT","781-797-0979","clinicaltrials@pepgen.com",[27,43,54],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"University of Calgary","RECRUITING","Calgary","Alberta","T2N 4Z6","Canada",{"type":35,"coordinates":36},"Point",[37,38],-114.08529,51.05011,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":24,"phoneExt":19,"email":25},"Patient Advocacy",{"facility":44,"status":29,"city":45,"state":46,"zip":19,"country":33,"cosmosGeoPoint":47,"geoPoint":51,"contacts":52},"Ottawa Hospital Research Institute","Ottawa","Ontario",{"type":35,"coordinates":48},[49,50],-75.69812,45.41117,{"lat":50,"lon":49},[53],{"name":42,"role":23,"phone":19,"phoneExt":19,"email":25},{"facility":55,"status":29,"city":56,"state":19,"zip":19,"country":33,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"CIUSSS du Saguenay-Lac-Saint-Jean","Saguenay",{"type":35,"coordinates":58},[59,60],-71.06573,48.41675,{"lat":60,"lon":59},[63],{"name":42,"role":23,"phone":19,"phoneExt":19,"email":25},{"type":65,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100609901",false,"NCT07220603","An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)","An Open-Label Extension Study Evaluating Safety and Pharmacokinetics in Participants With Myotonic Dystrophy Type 1 (FREEDOM-OLE)","Inclusion Criteria:\n\n* Participant has completed a prior study with PGN-EDODM1\n\nExclusion Criteria:\n\n* Abnormal laboratory tests at screening considered clinically significant by the Investigator\n* Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry","ALL",{"count":74,"type":75},48,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The purpose of this study is to learn about the long-term safety and tolerability of PGN-EDODM1 in participants with myotonic dystrophy type 1 (DM1) who have completed a prior study with PGN-EDODM1.",[81],"Myotonic Dystrophy 1",[83,81,84,85,9,86,87,88,89,90,91,92,93,94,95,96],"DM1","Myotonic Dystrophy","PepGen","Myotonic Muscular Dystrophy","Steinhert's Disease","Myotonic Dystrophies","Genetic Diseases, Inborn","Neuromuscular Diseases","Nervous System Diseases","Musculoskeletal Diseases","Myotonic Disorders","Muscular Disorders, Atrophic","Heredodegenerative Disorders, Nervous System","Muscular Diseases","2026-03-26",{"date":99,"type":100},"2026-03-30","ACTUAL",{"date":102,"type":100},"2025-12-23",{"date":104,"type":75},"2029-01",{"name":5,"class":6},3]